APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Inhaled NO Vasodilator

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Inhaled NO Vasodilator Market Outlook and Growth Opportunities 2026

2 January 2026194 pages

Choose your research edition.

Industry ResearchInhaled NO Vasodilator Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Inhaled NO Vasodilator Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Inhaled NO Vasodilator Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Inhaled NO Vasodilator Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Inhaled NO Vasodilator Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Inhaled NO Vasodilator market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Inhaled NO Vasodilator is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Inhaled NO Vasodilator is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Inhaled NO Vasodilator is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Inhaled NO Vasodilator market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Inhaled NO Vasodilator market include Air Liquide, BOC Healthcare (Linde Group), Mallinckrodt and Praxair (Linde plc), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Inhaled NO Vasodilator market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Inhaled NO Vasodilator and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Inhaled NO Vasodilator sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Inhaled NO Vasodilator market size, projected growth trends, production technologies, key applications, and end-use industries.

Inhaled NO Vasodilator Segment by Company

Air Liquide

BOC Healthcare (Linde Group)

Mallinckrodt

Praxair (Linde plc)

Inhaled NO Vasodilator Segment by Type

800 ppm

100 ppm

Others

Inhaled NO Vasodilator Segment by Application

PPHN

ARDS

Others

Inhaled NO Vasodilator Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Inhaled NO Vasodilator status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Inhaled NO Vasodilator market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Inhaled NO Vasodilator significant trends, drivers, influence factors in global and regions.

6. To analyze Inhaled NO Vasodilator competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inhaled NO Vasodilator market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Inhaled NO Vasodilator and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inhaled NO Vasodilator.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Inhaled NO Vasodilator market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Inhaled NO Vasodilator industry.

Chapter 3: Detailed analysis of Inhaled NO Vasodilator manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Inhaled NO Vasodilator in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Inhaled NO Vasodilator in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Inhaled NO Vasodilator Industry Trends Table 2. Inhaled NO Vasodilator Industry Drivers Table 3. Inhaled NO Vasodilator Industry Opportunities and Challenges Table 4. Inhaled NO Vasodilator Industry Restraints Table 5. Global Inhaled NO Vasodilator Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Inhaled NO Vasodilator Revenue Share by Company (2021-2026) Table 7. Global Inhaled NO Vasodilator Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Inhaled NO Vasodilator Sales Volume Share by Company (2021-2026) Table 9. Global Inhaled NO Vasodilator Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Inhaled NO Vasodilator Company Ranking, (2024-2026) & (USD Million) Table 11. Global Inhaled NO Vasodilator Key Company Manufacturing Base & Headquarters Table 12. Global Inhaled NO Vasodilator Company, Product Type & Application Table 13. Global Inhaled NO Vasodilator Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Inhaled NO Vasodilator by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 800 ppm Table 18. Significant Companies of 100 ppm Table 19. Significant Companies of Others Table 20. Global Inhaled NO Vasodilator Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Inhaled NO Vasodilator Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Inhaled NO Vasodilator Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Inhaled NO Vasodilator Sales Volume Share by Type (2021-2026) Table 24. Global Inhaled NO Vasodilator Sales Volume Share by Type (2027-2032) Table 25. Global Inhaled NO Vasodilator Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Inhaled NO Vasodilator Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Inhaled NO Vasodilator Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Inhaled NO Vasodilator Sales Value Share by Type (2021-2026) Table 29. Global Inhaled NO Vasodilator Sales Value Share by Type (2027-2032) Table 30. Significant Companies of PPHN Table 31. Significant Companies of ARDS Table 32. Significant Companies of Others Table 33. Global Inhaled NO Vasodilator Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Inhaled NO Vasodilator Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Inhaled NO Vasodilator Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Inhaled NO Vasodilator Sales Volume Share by Application (2021-2026) Table 37. Global Inhaled NO Vasodilator Sales Volume Share by Application (2027-2032) Table 38. Global Inhaled NO Vasodilator Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Inhaled NO Vasodilator Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Inhaled NO Vasodilator Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Inhaled NO Vasodilator Sales Value Share by Application (2021-2026) Table 42. Global Inhaled NO Vasodilator Sales Value Share by Application (2027-2032) Table 43. Global Inhaled NO Vasodilator Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Inhaled NO Vasodilator Sales by Region (2021-2026) & (K Units) Table 45. Global Inhaled NO Vasodilator Sales Market Share by Region (2021-2026) Table 46. Global Inhaled NO Vasodilator Sales by Region (2027-2032) & (K Units) Table 47. Global Inhaled NO Vasodilator Sales Market Share by Region (2027-2032) Table 48. Global Inhaled NO Vasodilator Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Inhaled NO Vasodilator Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Inhaled NO Vasodilator Sales Value Share by Region (2021-2026) Table 51. Global Inhaled NO Vasodilator Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Inhaled NO Vasodilator Sales Value Share by Region (2027-2032) Table 53. Global Inhaled NO Vasodilator Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Inhaled NO Vasodilator Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Inhaled NO Vasodilator Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Inhaled NO Vasodilator Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Inhaled NO Vasodilator Sales by Country (2021-2026) & (K Units) Table 58. Global Inhaled NO Vasodilator Sales Market Share by Country (2021-2026) Table 59. Global Inhaled NO Vasodilator Sales by Country (2027-2032) & (K Units) Table 60. Global Inhaled NO Vasodilator Sales Market Share by Country (2027-2032) Table 61. Global Inhaled NO Vasodilator Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Inhaled NO Vasodilator Sales Value Market Share by Country (2021-2026) Table 63. Global Inhaled NO Vasodilator Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Inhaled NO Vasodilator Sales Value Market Share by Country (2027-2032) Table 65. Air Liquide Company Information Table 66. Air Liquide Business Overview Table 67. Air Liquide Inhaled NO Vasodilator Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Air Liquide Inhaled NO Vasodilator Product Portfolio Table 69. Air Liquide Recent Development Table 70. BOC Healthcare (Linde Group) Company Information Table 71. BOC Healthcare (Linde Group) Business Overview Table 72. BOC Healthcare (Linde Group) Inhaled NO Vasodilator Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. BOC Healthcare (Linde Group) Inhaled NO Vasodilator Product Portfolio Table 74. BOC Healthcare (Linde Group) Recent Development Table 75. Mallinckrodt Company Information Table 76. Mallinckrodt Business Overview Table 77. Mallinckrodt Inhaled NO Vasodilator Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Mallinckrodt Inhaled NO Vasodilator Product Portfolio Table 79. Mallinckrodt Recent Development Table 80. Praxair (Linde plc) Company Information Table 81. Praxair (Linde plc) Business Overview Table 82. Praxair (Linde plc) Inhaled NO Vasodilator Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Praxair (Linde plc) Inhaled NO Vasodilator Product Portfolio Table 84. Praxair (Linde plc) Recent Development Table 85. Key Raw Materials Table 86. Raw Materials Key Suppliers Table 87. Inhaled NO Vasodilator Distributors List Table 88. Inhaled NO Vasodilator Customers List Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Inhaled NO Vasodilator Product Image Figure 2. Global Inhaled NO Vasodilator Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Inhaled NO Vasodilator Sales Value (2021-2032) & (US$ Million) Figure 4. Global Inhaled NO Vasodilator Sales (2021-2032) & (K Units) Figure 5. Global Inhaled NO Vasodilator Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Inhaled NO Vasodilator Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 800 ppm Image Figure 10. 100 ppm Image Figure 11. Others Image Figure 12. Global Inhaled NO Vasodilator Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Inhaled NO Vasodilator Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Inhaled NO Vasodilator Sales Volume Share by Type (2021-2032) Figure 15. Global Inhaled NO Vasodilator Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Inhaled NO Vasodilator Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Inhaled NO Vasodilator Sales Value Share by Type (2021-2032) Figure 18. PPHN Image Figure 19. ARDS Image Figure 20. Others Image Figure 21. Global Inhaled NO Vasodilator Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Inhaled NO Vasodilator Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Inhaled NO Vasodilator Sales Volume Share by Application (2021-2032) Figure 24. Global Inhaled NO Vasodilator Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Inhaled NO Vasodilator Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Inhaled NO Vasodilator Sales Value Share by Application (2021-2032) Figure 27. Global Inhaled NO Vasodilator Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Inhaled NO Vasodilator Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Inhaled NO Vasodilator Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Inhaled NO Vasodilator Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Inhaled NO Vasodilator Sales Value (2021-2032) & (US$ Million) Figure 32. North America Inhaled NO Vasodilator Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Inhaled NO Vasodilator Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Inhaled NO Vasodilator Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Inhaled NO Vasodilator Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Inhaled NO Vasodilator Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Inhaled NO Vasodilator Sales Value (2021-2032) & (US$ Million) Figure 38. South America Inhaled NO Vasodilator Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Inhaled NO Vasodilator Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Inhaled NO Vasodilator Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Inhaled NO Vasodilator Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Inhaled NO Vasodilator Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 800 ppm
  • 100 ppm
  • Others
Applications
  • PPHN
  • ARDS
  • Others
Companies covered
  • Air Liquide
  • BOC Healthcare (Linde Group)
  • Mallinckrodt
  • Praxair (Linde plc)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Inhaled NO Vasodilator Sales Value (2021-2032)
  4. 1.2.2 Global Inhaled NO Vasodilator Sales Volume (2021-2032)
  5. 1.2.3 Global Inhaled NO Vasodilator Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Inhaled NO Vasodilator Market Dynamics
  1. 2.1 Inhaled NO Vasodilator Industry Trends
  2. 2.2 Inhaled NO Vasodilator Industry Drivers
  3. 2.3 Inhaled NO Vasodilator Industry Opportunities and Challenges
  4. 2.4 Inhaled NO Vasodilator Industry Restraints
3 Inhaled NO Vasodilator Market by Company
  1. 3.1 Global Inhaled NO Vasodilator Company Revenue Ranking in 2025
  2. 3.2 Global Inhaled NO Vasodilator Revenue by Company (2021-2026)
  3. 3.3 Global Inhaled NO Vasodilator Sales Volume by Company (2021-2026)
  4. 3.4 Global Inhaled NO Vasodilator Average Price by Company (2021-2026)
  5. 3.5 Global Inhaled NO Vasodilator Company Ranking (2024-2026)
  6. 3.6 Global Inhaled NO Vasodilator Company Manufacturing Base and Headquarters
  7. 3.7 Global Inhaled NO Vasodilator Company Product Type and Application
  8. 3.8 Global Inhaled NO Vasodilator Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Inhaled NO Vasodilator Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Inhaled NO Vasodilator Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Inhaled NO Vasodilator Market by Type
  1. 4.1 Inhaled NO Vasodilator Type Introduction
  2. 4.1.1 800 ppm
  3. 4.1.2 100 ppm
  4. 4.1.3 Others
  5. 4.2 Global Inhaled NO Vasodilator Sales Volume by Type
  6. 4.2.1 Global Inhaled NO Vasodilator Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Inhaled NO Vasodilator Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Inhaled NO Vasodilator Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Inhaled NO Vasodilator Sales Value by Type
  10. 4.3.1 Global Inhaled NO Vasodilator Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Inhaled NO Vasodilator Sales Value by Type (2021-2032)
  12. 4.3.3 Global Inhaled NO Vasodilator Sales Value Share by Type (2021-2032)
5 Inhaled NO Vasodilator Market by Application
  1. 5.1 Inhaled NO Vasodilator Application Introduction
  2. 5.1.1 PPHN
  3. 5.1.2 ARDS
  4. 5.1.3 Others
  5. 5.2 Global Inhaled NO Vasodilator Sales Volume by Application
  6. 5.2.1 Global Inhaled NO Vasodilator Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Inhaled NO Vasodilator Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Inhaled NO Vasodilator Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Inhaled NO Vasodilator Sales Value by Application
  10. 5.3.1 Global Inhaled NO Vasodilator Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Inhaled NO Vasodilator Sales Value by Application (2021-2032)
  12. 5.3.3 Global Inhaled NO Vasodilator Sales Value Share by Application (2021-2032)
6 Inhaled NO Vasodilator Regional Sales and Value Analysis
  1. 6.1 Global Inhaled NO Vasodilator Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Inhaled NO Vasodilator Sales by Region (2021-2032)
  3. 6.2.1 Global Inhaled NO Vasodilator Sales by Region: 2021-2026
  4. 6.2.2 Global Inhaled NO Vasodilator Sales by Region (2027-2032)
  5. 6.3 Global Inhaled NO Vasodilator Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Inhaled NO Vasodilator Sales Value by Region (2021-2032)
  7. 6.4.1 Global Inhaled NO Vasodilator Sales Value by Region: 2021-2026
  8. 6.4.2 Global Inhaled NO Vasodilator Sales Value by Region (2027-2032)
  9. 6.5 Global Inhaled NO Vasodilator Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Inhaled NO Vasodilator Sales Value (2021-2032)
  12. 6.6.2 North America Inhaled NO Vasodilator Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Inhaled NO Vasodilator Sales Value (2021-2032)
  15. 6.7.2 Europe Inhaled NO Vasodilator Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Inhaled NO Vasodilator Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Inhaled NO Vasodilator Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Inhaled NO Vasodilator Sales Value (2021-2032)
  21. 6.9.2 South America Inhaled NO Vasodilator Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Inhaled NO Vasodilator Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Inhaled NO Vasodilator Sales Value Share by Country, 2025 VS 2032
7 Inhaled NO Vasodilator Country-level Sales and Value Analysis
  1. 7.1 Global Inhaled NO Vasodilator Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Inhaled NO Vasodilator Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Inhaled NO Vasodilator Sales by Country (2021-2032)
  4. 7.3.1 Global Inhaled NO Vasodilator Sales by Country (2021-2026)
  5. 7.3.2 Global Inhaled NO Vasodilator Sales by Country (2027-2032)
  6. 7.4 Global Inhaled NO Vasodilator Sales Value by Country (2021-2032)
  7. 7.4.1 Global Inhaled NO Vasodilator Sales Value by Country (2021-2026)
  8. 7.4.2 Global Inhaled NO Vasodilator Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Inhaled NO Vasodilator Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Inhaled NO Vasodilator Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Inhaled NO Vasodilator Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Air Liquide
  2. 8.1.1 Air Liquide Company Information
  3. 8.1.2 Air Liquide Business Overview
  4. 8.1.3 Air Liquide Inhaled NO Vasodilator Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Air Liquide Inhaled NO Vasodilator Product Portfolio
  6. 8.1.5 Air Liquide Recent Developments
  7. 8.2 BOC Healthcare (Linde Group)
  8. 8.2.1 BOC Healthcare (Linde Group) Company Information
  9. 8.2.2 BOC Healthcare (Linde Group) Business Overview
  10. 8.2.3 BOC Healthcare (Linde Group) Inhaled NO Vasodilator Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 BOC Healthcare (Linde Group) Inhaled NO Vasodilator Product Portfolio
  12. 8.2.5 BOC Healthcare (Linde Group) Recent Developments
  13. 8.3 Mallinckrodt
  14. 8.3.1 Mallinckrodt Company Information
  15. 8.3.2 Mallinckrodt Business Overview
  16. 8.3.3 Mallinckrodt Inhaled NO Vasodilator Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mallinckrodt Inhaled NO Vasodilator Product Portfolio
  18. 8.3.5 Mallinckrodt Recent Developments
  19. 8.4 Praxair (Linde plc)
  20. 8.4.1 Praxair (Linde plc) Company Information
  21. 8.4.2 Praxair (Linde plc) Business Overview
  22. 8.4.3 Praxair (Linde plc) Inhaled NO Vasodilator Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Praxair (Linde plc) Inhaled NO Vasodilator Product Portfolio
  24. 8.4.5 Praxair (Linde plc) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Inhaled NO Vasodilator Value Chain Analysis
  2. 9.1.1 Inhaled NO Vasodilator Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Inhaled NO Vasodilator Sales Mode & Process
  6. 9.2 Inhaled NO Vasodilator Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Inhaled NO Vasodilator Distributors
  9. 9.2.3 Inhaled NO Vasodilator Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst